An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group

Transplantation

Volumn 62, Issue 7, 1996, Pages 900-905

  Laskow, David A ^a,b   Vincenti, Flavio ^c   Neylan, John F ^d   Mendez, Robert ^e   Matas, Arthur J ^f  

^a Kentucky   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e National Institute of Transplantation Los Angeles   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; OKT 3; TACROLIMUS;

ADULT; ARTICLE; CADAVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 0029805879     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00005     Document Type: Article

References (36)

1. UNOS. UNOS releases 1993 transplant statistics. UNOS Update 1994.
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
3. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
4. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40: 1249.
5. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40: 1256.
6. Goto T, Kino T, Hatanaka M, et al. FK506: Historical perspectives. Transplant Proc 1991; 23: 2713.
7. Sigal NH, Lin CS, Siekierka JJ. Inhibition of human T-cell activation by FK506, rapamycin, and cyclosporine A. Transplant Proc 1991; 23: 1.
8. Jiang H, Suguo H, Takahara S, et al. Combined immunosuppressive effect of FK506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant Proc 1991; 23: 2933.
9. Jiang H, Takahara S, Takano Y, et al. Effect of FK506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. Transplant Proc 1991; 23: 540.
10. Tsuchimoto S, Kusumoto K, Nakajiwa Y, et al. Orthotopic liver transplantation in rats receiving FK506. Transplant Proc 1989; 21: 1064.
11. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729.
12. Ochiai T, Nagata M, Nakajima K, Sakamoto K, Asano T, Isono K. Prolongation of canine renal allograft survival by treatment with FK-506. Transplant Proc 1987; 19: 53.
13. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressant agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19: 1284.
14. Isai H, Painter DM, Shell AGR. FK506 and orthotopic liver transplantation in the rat. Transplant Proc 1990; 22: 2125.
15. Armitage JM, Fricker FJ, Del Nido P, Cipriani L, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23: 3058.
16. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23: 3054.
17. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
18. Jensen CWB, Jordan ML, Schneck FX, et al. Pediatric renal transplantation under FK506 immunosuppression. Transplant Proc 1991; 23: 3075.
19. Jordan JL, Shapiro R, Vivas CA, et al. FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 1993; 25: 638.
20. Shapiro R, Jordan M, Scantlebury V, et al. FK506 in clinical kidney transplantation. Transplant Proc 1991; 23: 3065.
21. Shapiro R, Jordan ML, Scantlebury, et al. Randomized trial of FK506/prednisone vs FK506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 1993; 25: 669.
22. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of late phase II study. Transplant Proc 1993; 25: 649.
23. Japanese FK506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under FK506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK506 nephrotoxicity. Transplant Proc 1993; 25: 624.
24. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23: 3105.
25. Tauxe WN, Mochizuki T, McCauley J, Starzl TE, Jain A, Charron M. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. Transplant Proc 1991; 23: 3146.
26. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 1993; 17: 60.
27. McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE. Changes in renal function after liver transplantation under FK 506. Transplant Proc 1991; 23: 3143.
28. Jusko WJ, D'Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 1991; 23: 2732.
29. Kobayashi M, Tamura K, Katayama N, et al. FK506 assay past and present characteristics of FK506 ELISA. Transplant Proc 1991; 23: 2725.
30. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc 1991; 23: 2748.
31. Luke RG. New issues in therapy after renal transplantation. N Engl J Med 1994; 331; 393.
32. Kupin WL, Venkat KK, Norris C, et al. Effective long-term immunosuppression maintained by low cyclosporine levels in primary cadaveric renal transplant recipients. Transplantation 1987; 43: 214.
33. Brinker KR, Dickerman RM, Gonwa TA, et al. A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 1990; 50: 43.
34. Canafax DM, Min DI, Gruber SA, et al. Immunosuppression for cadaveric renal allograft recipients: a risk-factor matched comparison of the Minnesota Randomized Trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol. Clin Transplant 1989; 3: 110.
35. Japanese FK506 Study Group. Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK506. Transplant Proc 1991; 23: 3111.
36. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.